Follistatin fusion protein
JP2025520393A5Pending Publication Date: 2026-06-15UCB BIOPHARMA SPRL
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- UCB BIOPHARMA SPRL
- Filing Date
- 2023-06-14
- Publication Date
- 2026-06-15
AI Technical Summary
⚠Technical Problem
Existing follistatin-based therapies face challenges due to difficulties in expressing follistatin in vitro and its short half-life in vivo, limiting its therapeutic potential.
⚗Method used
Development of follistatin fusion proteins incorporating an antigen-binding antibody portion, such as Fab, which enhances expression and stability by binding to albumin, thereby improving half-life and efficacy.
🎯Benefits of technology
The fusion proteins exhibit improved expression levels and extended half-life, maintaining biological activity and inhibitory effects on activin ligands, making them more effective therapeutic agents.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to the field of fusion proteins, and particularly to fusion proteins containing a follistatin moiety. The present invention also relates to a method for producing the fusion protein, together with a pharmaceutical preparation containing the fusion protein.
Need to check novelty before this filing date? Find Prior Art